GSTO1‐OE increased cisplatin resistance, whereas GSTO1‐KO or the GSTO1 inhibitor GSTO1‐IN‐1 sensitized bladder cancer to cisplatin (Fig. 3D–F). Here, GSTO1 is linked to urinary bladder cancer.